These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 26891930)

  • 1. Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance.
    Tekchandani P; Kurmi BD; Paliwal SR
    Mini Rev Med Chem; 2017; 17(18):1793-1810. PubMed ID: 26891930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming multidrug resistance with nanomedicines.
    Ganoth A; Merimi KC; Peer D
    Expert Opin Drug Deliv; 2015 Feb; 12(2):223-38. PubMed ID: 25224685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomaterial-induced autophagy: a new reversal MDR tool in cancer therapy?
    Panzarini E; Dini L
    Mol Pharm; 2014 Aug; 11(8):2527-38. PubMed ID: 24921216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR.
    Mohammad IS; He W; Yin L
    Biomed Pharmacother; 2018 Apr; 100():335-348. PubMed ID: 29453043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology.
    Xue X; Liang XJ
    Chin J Cancer; 2012 Feb; 31(2):100-9. PubMed ID: 22237039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic potential of targeting ABC transporters to combat multi-drug resistance.
    Bugde P; Biswas R; Merien F; Lu J; Liu DX; Chen M; Zhou S; Li Y
    Expert Opin Ther Targets; 2017 May; 21(5):511-530. PubMed ID: 28335655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance: Physiological principles and nanomedical solutions.
    Kunjachan S; Rychlik B; Storm G; Kiessling F; Lammers T
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1852-1865. PubMed ID: 24120954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicine to overcome cancer multidrug resistance.
    Yang X; Yi C; Luo N; Gong C
    Curr Drug Metab; 2014; 15(6):632-49. PubMed ID: 25255871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel nanomedicines to overcome cancer multidrug resistance.
    Su Z; Dong S; Zhao SC; Liu K; Tan Y; Jiang X; Assaraf YG; Qin B; Chen ZS; Zou C
    Drug Resist Updat; 2021 Sep; 58():100777. PubMed ID: 34481195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicines for combating multidrug resistance of cancer.
    Zhu YX; Jia HR; Duan QY; Wu FG
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Sep; 13(5):e1715. PubMed ID: 33860622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanisms of multidrug resistance in cancer chemotherapy.
    Nooter K; Stoter G
    Pathol Res Pract; 1996 Jul; 192(7):768-80. PubMed ID: 8880878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression.
    Nobili S; Landini I; Mazzei T; Mini E
    Med Res Rev; 2012 Nov; 32(6):1220-62. PubMed ID: 21374643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
    Beretta GL; Cavalieri F
    Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversion of multidrug resistance by a pH-responsive cyclodextrin-derived nanomedicine in drug resistant cancer cells.
    Shi Q; Zhang L; Liu M; Zhang X; Zhang X; Xu X; Chen S; Li X; Zhang J
    Biomaterials; 2015 Oct; 67():169-82. PubMed ID: 26218743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nano-based strategies to overcome p-glycoprotein-mediated drug resistance.
    Niazi M; Zakeri-Milani P; Najafi Hajivar S; Soleymani Goloujeh M; Ghobakhlou N; Shahbazi Mojarrad J; Valizadeh H
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1021-33. PubMed ID: 27267126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanocarriers overcoming biological barriers induced by multidrug resistance of chemotherapeutics in 2D and 3D cancer models.
    Petrikaite V; D'Avanzo N; Celia C; Fresta M
    Drug Resist Updat; 2023 May; 68():100956. PubMed ID: 36958083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
    Kibria G; Hatakeyama H; Harashima H
    Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.